Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals – TheStreet.com
TheStreet.com |
Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals
TheStreet.com Incyte (INCY) is benefitting from the competition between Merck (MRK) and Bristol-Myers Squibb (BMY) for cancer immunotherapy supremacy. On Sunday, Bristol and Incyte announced plans to test a combination therapy consisting of the Big Pharma's … Merck's Keytruda cancer drug records sales surge The cost of cancer: new drugs show success at a steep price |
